donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > FGEN FibroGen > Company Executives
FGEN FibroGen
11.400
+0.840+7.95%
Post Mkt Price
11.40000.00%
NamePositionSalaryService DateEducationAgeGenderUpdated
Mr. Enrique A. ConternoDirector and Chief Executive Officer------54male02/28/2022
Mr. Thane WettigChief Commercial Officer------56male04/13/2021
Mr. Mark EisnerChief Medical Officer------55male04/13/2021
Mr. Juan GrahamSenior Vice President and Chief Financial Officer------46male02/28/2022
Ms. Christine ChungSenior Vice President, China Operations------53female04/13/2021
Mr. Elias KouchakjiSenior Vice President, Clinical Development, Drug Safety and Pharmacovigilance------65male04/13/2021
Mr. James A. SchoeneckChairman of the Board------63male02/28/2022
Mr. Thomas F. Kearns, JrIndependent Director283.02K----84male06/08/2022
Mr. Jeffrey L. EdwardsIndependent Director------60male02/28/2022
Mr. Jeffrey W. HendersonIndependent Director261.67K----56male02/28/2022
Mr. Rory B. RiggsIndependent Director------67male02/28/2022
Dr. Maykin HoIndependent Director------68female02/28/2022
Dr. Aoife M. Brennan, M.B.Independent Director------45female02/28/2022
Mr. Gerald LemaIndependent Director676.56K----60male02/28/2022
Ms. Suzanne BlaugIndependent Director------63female02/28/2022
Mr. Benjamin CravattIndependent Director------51male02/28/2022
Company Overview More
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
CEO: Conterno, Enrique A.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...